Elevation Oncology, Inc.(NASDAQ : ELEV)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-2.32%||10.52||0.7%||$735.39m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.60%||201.58||1.9%||$414.73m|
|GILD||Gilead Sciences, Inc.||-2.21%||68.29||1.0%||$401.30m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.46%||574.61||2.7%||$353.89m|
|NTLA||Intellia Therapeutics, Inc.||3.53%||141.85||2.3%||$263.90m|
|CRSP||CRISPR Therapeutics AG||1.70%||121.02||0.6%||$144.72m|
|EXAS||EXACT Sciences Corp.||-3.64%||107.84||18.1%||$123.59m|
Elevation Oncology, Inc. operates as a precision oncology company. It focuses on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firmâ€™s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in New York, NY.